165 related articles for article (PubMed ID: 30708041)
21. Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer.
Zacharias NM; McCullough C; Shanmugavelandy S; Lee J; Lee Y; Dutta P; McHenry J; Nguyen L; Norton W; Jones LW; Bhattacharya PK
Sci Rep; 2017 Nov; 7(1):16159. PubMed ID: 29170516
[TBL] [Abstract][Full Text] [Related]
22. Selective amino acid restriction targets mitochondria to induce apoptosis of androgen-independent prostate cancer cells.
Fu YM; Zhang H; Ding M; Li YQ; Fu X; Yu ZX; Meadows GG
J Cell Physiol; 2006 Nov; 209(2):522-34. PubMed ID: 16897757
[TBL] [Abstract][Full Text] [Related]
23. Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate.
Dueregger A; Schöpf B; Eder T; Höfer J; Gnaiger E; Aufinger A; Kenner L; Perktold B; Ramoner R; Klocker H; Eder IE
PLoS One; 2015; 10(8):e0135704. PubMed ID: 26285134
[TBL] [Abstract][Full Text] [Related]
24. Incorporating imaging into personalized medicine for the detection of prostate cancer: Pharmacological research-Urogenital pharmacology.
Mertan F; Turkbey B
Pharmacol Res; 2016 Dec; 114():163-165. PubMed ID: 27777131
[TBL] [Abstract][Full Text] [Related]
25. The Metabolic Phenotype of Prostate Cancer.
Eidelman E; Twum-Ampofo J; Ansari J; Siddiqui MM
Front Oncol; 2017; 7():131. PubMed ID: 28674679
[TBL] [Abstract][Full Text] [Related]
26. Prostate cancer molecular profiling: the Achilles heel for the implementation of precision medicine.
Oliveira-Barros EG; Nicolau-Neto P; Da Costa NM; Pinto LFR; Palumbo A; Nasciutti LE
Cell Biol Int; 2017 Nov; 41(11):1239-1245. PubMed ID: 28477422
[TBL] [Abstract][Full Text] [Related]
27. Steroid biosynthesis and prostate cancer.
Sharifi N; Auchus RJ
Steroids; 2012 Jun; 77(7):719-26. PubMed ID: 22503713
[TBL] [Abstract][Full Text] [Related]
28. Is the Response of Tumours Dependent on the Dietary Input of Some Amino Acids or Ratios among Essential and Non-Essential Amino Acids? All That Glitters Is Not Gold.
Dioguardi FS; Flati V; Corsetti G; Pasini E; Romano C
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30453654
[TBL] [Abstract][Full Text] [Related]
29. Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect.
Sun L; Suo C; Li ST; Zhang H; Gao P
Biochim Biophys Acta Rev Cancer; 2018 Aug; 1870(1):51-66. PubMed ID: 29959989
[TBL] [Abstract][Full Text] [Related]
30. Specific amino acid dependency regulates invasiveness and viability of androgen-independent prostate cancer cells.
Fu YM; Yu ZX; Li YQ; Ge X; Sanchez PJ; Fu X; Meadows GG
Nutr Cancer; 2003; 45(1):60-73. PubMed ID: 12791506
[TBL] [Abstract][Full Text] [Related]
31. [Personalized medicine and prostate cancer. The reality of change].
Carballido Rodríguez JA; Martínez-Salamanca JI
Arch Esp Urol; 2015 Apr; 68(3):391-400. PubMed ID: 25948808
[TBL] [Abstract][Full Text] [Related]
32. Glycine consumption and mitochondrial serine hydroxymethyltransferase in cancer cells: the heme connection.
di Salvo ML; Contestabile R; Paiardini A; Maras B
Med Hypotheses; 2013 May; 80(5):633-6. PubMed ID: 23474074
[TBL] [Abstract][Full Text] [Related]
33. Androgen control of lipid metabolism in prostate cancer: novel insights and future applications.
Butler LM; Centenera MM; Swinnen JV
Endocr Relat Cancer; 2016 May; 23(5):R219-27. PubMed ID: 27130044
[TBL] [Abstract][Full Text] [Related]
34. Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.
Alvarez-Cubero MJ; Martinez-Gonzalez LJ; Robles-Fernandez I; Martinez-Herrera J; Garcia-Rodriguez G; Pascual-Geler M; Cozar JM; Lorente JA
Mol Diagn Ther; 2017 Apr; 21(2):167-178. PubMed ID: 27995550
[TBL] [Abstract][Full Text] [Related]
35. Amino Acid Profiling of Zinc Resistant Prostate Cancer Cell Lines: Associations With Cancer Progression.
Kratochvilova M; Raudenska M; Heger Z; Richtera L; Cernei N; Adam V; Babula P; Novakova M; Masarik M; Gumulec J
Prostate; 2017 May; 77(6):604-616. PubMed ID: 28101932
[TBL] [Abstract][Full Text] [Related]
36. Organ-Specific Cancer Metabolism and Its Potential for Therapy.
Elia I; Schmieder R; Christen S; Fendt SM
Handb Exp Pharmacol; 2016; 233():321-53. PubMed ID: 25912014
[TBL] [Abstract][Full Text] [Related]
37. Cell metabolomics identify regulatory pathways and targets of magnoline against prostate cancer.
Sun H; Zhang AH; Liu SB; Qiu S; Li XN; Zhang TL; Liu L; Wang XJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Dec; 1102-1103():143-151. PubMed ID: 30391728
[TBL] [Abstract][Full Text] [Related]
38. Pathology and molecular updates in tumors of the prostate: towards a personalized approach.
Gasparrini S; Cimadamore A; Mazzucchelli R; Scarpelli M; Massari F; Raspollini MR; Galosi AB; Lopez-Beltran A; Cheng L; Montironi R
Expert Rev Mol Diagn; 2017 Aug; 17(8):781-789. PubMed ID: 28598696
[TBL] [Abstract][Full Text] [Related]
39. The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy.
Costello LC; Franklin RB
Oncology; 2000 Nov; 59(4):269-82. PubMed ID: 11096338
[TBL] [Abstract][Full Text] [Related]
40. How does metabolism affect cell death in cancer?
Villa E; Ricci JE
FEBS J; 2016 Jul; 283(14):2653-60. PubMed ID: 26498911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
